Inspections, Compliance, Enforcement, and Criminal Investigations
Michigan Trading Post 18-Dec-01
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration
4040 North Central Expressway
Dallas, Texas 75204-3145
December 18, 2001
RETURNED RECEIPT REQUESTED
Mr. Douglass A Witters, Esq.
Pollard & Albertson
Michigan Trading Post Inc.
38505 N. Woodward Avenue, Suite 2300
Bloomfield Hills, Ml 48304
Dear Mr. Witters:
This letter is in reference to your firm?s marketing and distribution of NexCite dietary
supplement. Labeling for this product causes it to be a misbranded food [section 403 of the Federal Food Drug, and Cosmetic Act (the Act)]. Labeling is not limited to the immediate product containers but includes all promotional literature, distributed with your product and ?any Internet promotions of your product.
Objectionable labeling for NexCite dietary supplement includes the following:
1. The product is misbranded under section 403(q)(5)(F) of the Act and 21 CFR
101.36 because it bears nutrition labeling that does not include all dietary ingredients (i.e., caffeine) in the supplement facts nutrition panel. It also declares dietary ingredients (i.e., caffeine) outside of the supplements facts panel.
2. The product is misbranded under section 403(s)(2)(B) because it is not labeled in
accordance with section 201 (ff)(2)(C) of the Act and 21 CFR 101.3(g) in that the
statement of identity does not include the term "dietary supplement". Further, the
prominence of the term "dietary supplement" does not meet the labeling
requirements of 21 CFR 101.3(d).
3. The product is misbranded under section 403(i)(2) and 21 CFR 101.4(a)(1) in that
it claims to have a fruit taste made from a blend of peaches, raspberry, lemon and
passion fruit, but these ingredients are not declared in the ingredient listing of the
4. The product is misbranded under section 403(r)(l)(A) in that it bears the unauthorized nutrient content claim "with caffeine".
This letter is not intended to be an all-inclusive review of all labeling and products your firm may market. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations.
We request that you take prompt action to correct these violations. Failure to promptly
Correct these violations may result in enforcement action being initiated by the Food and
Drug Administration without further notice. The Federal Food, Drug and Cosmetic Act
provides for the seizure of illegal products and for injunction against the manufacturer
and/or distributor of illegal products.
Please notify this office in writing within fifteen (15) working days of receipt of this letter as to the specific steps you have taken to correct the stated violations, including an
explanation of each step being taken to identify and make corrections to assure that similar violations will not recur. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be implemented.
Your reply should be sent to the attention of Compliance Officer, Brenda C. Baumert at the above letterhead address.
Michael A Chappell